Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Di Cosimo

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 3, 2013
Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implicationsF Montemurro, S Di Cosimo, G Arpino
La Clinica Terapeutica|December 1, 2001
Huge response to letrozole in inoperable T4 breast cancer: a case reportS Di Cosimo, V Altomare, G Ferretti, et al.
Critical Reviews in Oncology/Hematology|December 31, 2013
Targeted therapy-induced diarrhea: A review of the literatureM A Pessi, N Zilembo, E R Haspinger, et al.
La Clinica Terapeutica|January 6, 2001
Atypical case of metastatic undifferentiated prostate carcinoma in a 36 years old man: clinical report and literature reviewM D'Aprile, D Santini, S Di Cosimo, et al.
Onkologie|July 8, 2003
Fatal thrombocytopenia and thrombocytopathia: an unusual onset of non-small cell lung cancerG Tonini, B Vincenzi, S Di Cosimo, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 26, 2005
Midazolam for acute emesis refractory to dexamethasone and granisetron after highly emetogenic chemotherapy: a phase II studyM Mandalà, M Cremonesi, A Rocca, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 10, 2000
Gemcitabine-induced atrial fibrillation: a hitherto unreported manifestation of drug toxicityD Santini, G Tonini, A Abbate, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 22, 2015
Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapiesD Serpico, L Porcu, A Tessari, et al.
Minerva Medica|August 4, 2004
[Preclinical and clinical results with the epidermal growth factor receptor inhibitor Gefitinib (ZD1839, Iressa)]S Di Cosimo, G Ferretti, M Milella, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 10, 2013
Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trialC Criscitiello, H A Azim, D Agbor-tarh, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 3, 2013
Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implicationsF Montemurro, S Di Cosimo, G Arpino
La Clinica Terapeutica|December 1, 2001
Huge response to letrozole in inoperable T4 breast cancer: a case reportS Di Cosimo, V Altomare, G Ferretti, et al.
Critical Reviews in Oncology/Hematology|December 31, 2013
Targeted therapy-induced diarrhea: A review of the literatureM A Pessi, N Zilembo, E R Haspinger, et al.
La Clinica Terapeutica|January 6, 2001
Atypical case of metastatic undifferentiated prostate carcinoma in a 36 years old man: clinical report and literature reviewM D'Aprile, D Santini, S Di Cosimo, et al.
Onkologie|July 8, 2003
Fatal thrombocytopenia and thrombocytopathia: an unusual onset of non-small cell lung cancerG Tonini, B Vincenzi, S Di Cosimo, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 26, 2005
Midazolam for acute emesis refractory to dexamethasone and granisetron after highly emetogenic chemotherapy: a phase II studyM Mandalà, M Cremonesi, A Rocca, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 10, 2000
Gemcitabine-induced atrial fibrillation: a hitherto unreported manifestation of drug toxicityD Santini, G Tonini, A Abbate, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 22, 2015
Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapiesD Serpico, L Porcu, A Tessari, et al.
Minerva Medica|August 4, 2004
[Preclinical and clinical results with the epidermal growth factor receptor inhibitor Gefitinib (ZD1839, Iressa)]S Di Cosimo, G Ferretti, M Milella, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 10, 2013
Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trialC Criscitiello, H A Azim, D Agbor-tarh, et al.
Pageof 4